Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Protein Sciences Corporation Stories

2013-11-13 16:26:33

Ready for Immediate Delivery MERIDEN, Conn., Nov. 13, 2013 /PRNewswire/ -- Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available. Quantities of Flublok are limited and will be distributed on a first-come, first-served basis exclusively by...

2013-10-10 12:28:01

MERIDEN, Conn., Oct. 10, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that they expect the first doses of Flublok influenza vaccine for the 2013/2014 season to be released in time for vaccinations to occur prior to Thanksgiving. According to the Centers for Disease Control and Prevention (CDC), influenza activity typically peaks in January or later. It takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza...

2013-06-21 16:22:53

MERIDEN, Conn., June 21, 2013 /PRNewswire/ -- Protein Sciences announced today that the Advisory Committee on Immunization Practices (ACIP), which advises the U.S. Centers for Disease Control and Prevention (CDC), passed a measure recommending the use of Flublok Influenza Vaccine for adults age 18 through 49 who have an egg allergy, regardless of severity. The unanimous 13-0 vote shows unprecedented support for the use of a specific flu vaccine in this population. Flublok is the...

2013-05-02 12:28:42

Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...

2013-02-20 12:26:26

MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey, DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs. Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy. He was also responsible for developing...

2013-02-15 16:23:21

PEARL RIVER, N.Y., Feb. 15, 2013 /PRNewswire/ -- At a press conference today showcasing Protein Sciences' newly leased manufacturing facility for Flublok, the Company announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, will continue to support the Company's influenza vaccines program. BARDA held an internal review of the Protein Sciences program and made a decision to modify its contract with the...

2013-01-16 20:21:40

MERIDEN, Conn., Jan. 16, 2013 /PRNewswire/ -- The U.S. FDA approved Flublok for people 18-49 years old - making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013. Flublok features: First influenza vaccine made without the use of live influenza virus First egg-free influenza vaccine Highly purified without preservatives (thimerosal), antibiotics or adjuvants Three times the active ingredient...

2012-10-24 07:32:12

MERIDEN, Conn., Oct. 24, 2012 /PRNewswire/ -- Protein Sciences announced that Tim Fields, Vice President of Quality, was named recipient of the Ken Chapman Industry Recognition Award during the International Validation Week Conference presented by the Institute of Validation Technology (IVT) on Oct. 23, 2012. Ken Chapman who died of pancreatic cancer in 2006 was renowned for his forward-thinking approach to regulatory issues and best practices. Many of his ideas have become standard in...

2012-09-10 06:29:58

MERIDEN, Conn., Sept. 10, 2012 /PRNewswire/ -- Protein Sciences Corporation announced that this afternoon there will be a presentation of clinical data for the pandemic (monovalent) formulation of Protein Sciences innovative solution for protection from influenza, FluBlok, by John Treanor, MD, Chief of the Infectious Diseases Division of the Department of Medicine at the University of Rochester Medical Center. The presentation will occur at the Interscience Conference on Antimicrobial Agents...

2012-06-18 02:28:25

AMSTERDAM, The Netherlands, June 18, 2012 /PRNewswire/ -- uniQure, a leader in the field of human gene therapy, announced today the extension of its collaboration with Protein Sciences Corporation ("Protein Sciences") for the exclusive use of Protein Sciences' expresSF+(R) (SF+) insect cell line in uniQure's AAV gene therapy programs for three specific disease indications. uniQure has the option to extend this exclusivity further into additional indications in the future....